These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 10796870

  • 1. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M, Bennett C, Nicolucci A, Williams R.
    Cochrane Database Syst Rev; 2000; 1996(2):CD002182. PubMed ID: 10796870
    [Abstract] [Full Text] [Related]

  • 2. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M, Bennett C, Nicolucci A, Williams R.
    Cochrane Database Syst Rev; 1996 Apr 22; (1):CD002182. PubMed ID: 17636697
    [Abstract] [Full Text] [Related]

  • 3. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozzi D, Mari E, Benedetti MM, Tognoni G, Liberati A.
    Diabet Med; 1996 Dec 22; 13(12):1017-26. PubMed ID: 8973882
    [Abstract] [Full Text] [Related]

  • 4. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
    Chalk C, Benstead TJ, Moore F.
    Cochrane Database Syst Rev; 2007 Oct 17; 2007(4):CD004572. PubMed ID: 17943821
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, SNK-860 Diabetic Neuropathy Study Group.
    Diabetes Care; 2001 Oct 17; 24(10):1776-82. PubMed ID: 11574441
    [Abstract] [Full Text] [Related]

  • 6. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.
    Diabetes Care; 2006 Jul 17; 29(7):1538-44. PubMed ID: 16801576
    [Abstract] [Full Text] [Related]

  • 7. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K, Kohara N, Baba M, Komori T, Naito Y, Imai T, Satoh J, Yamaguchi Y, Hamatani T, Ranirestat Group.
    J Diabetes Investig; 2019 Mar 17; 10(2):466-474. PubMed ID: 29975462
    [Abstract] [Full Text] [Related]

  • 8. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
    Gabbay KH.
    Curr Diab Rep; 2004 Dec 17; 4(6):405-8. PubMed ID: 15539002
    [Abstract] [Full Text] [Related]

  • 9. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosén I, Sönksen P.
    J Diabetes Complications; 1992 Dec 17; 6(2):123-30. PubMed ID: 1611136
    [Abstract] [Full Text] [Related]

  • 10. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE, Padiyara RS, D'Souza JJ.
    J Diabetes Complications; 2010 Dec 17; 24(5):354-60. PubMed ID: 19748287
    [Abstract] [Full Text] [Related]

  • 11. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
    Masson EA, Boulton AJ.
    Drugs; 1990 Feb 17; 39(2):190-202. PubMed ID: 2109678
    [Abstract] [Full Text] [Related]

  • 12. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H, Miki T, Kyogoku I, Kawagishi T, Inaba M, Okuno Y, Nishizawa Y, Morii H.
    No To Shinkei; 1998 Sep 17; 50(9):817-20. PubMed ID: 9789304
    [Abstract] [Full Text] [Related]

  • 13. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y.
    J Diabetes Complications; 1996 Sep 17; 10(3):168-72. PubMed ID: 8807467
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V, Buchanan RA.
    Diabetes Care; 2006 Jan 17; 29(1):68-72. PubMed ID: 16373898
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
    Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, Lachin JM.
    Diabetes Care; 1996 Oct 17; 19(10):1091-6. PubMed ID: 8886554
    [Abstract] [Full Text] [Related]

  • 16. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB, Towle VL, Maselli R, Herold K.
    Metabolism; 1986 Apr 17; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [Abstract] [Full Text] [Related]

  • 17. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb 17; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 18. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
    Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M.
    Diabet Med; 1992 Jun 17; 9(5):463-8. PubMed ID: 1611835
    [Abstract] [Full Text] [Related]

  • 19. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N, Kawamori R, Fukuda M, Shigeta Y, Aldose Reductase Inhibitor-Diabetes Complications Trial Study Group.
    Diabet Med; 2012 Dec 17; 29(12):1529-33. PubMed ID: 22507139
    [Abstract] [Full Text] [Related]

  • 20. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA.
    J Diabetes Complications; 1992 Dec 17; 6(1):35-8. PubMed ID: 1562756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.